Aardvark Therapeutics, Inc.
NMS: AARDLive Quote
📈 ZcoreAI Score
Our AI model analyzes Aardvark Therapeutics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get AARD Z-Score →About Aardvark Therapeutics, Inc.
Healthcare
Biotechnology
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
📊 Fundamental Analysis
Aardvark Therapeutics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -64.4%, which indicates that capital utilization is currently under pressure.
At a current price of $3.94, AARD currently trades near the bottom of its 52-week range (4%), indicating potential value or weakness (Range: $3.35 - $17.94).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Return on Equity
Weak
Key Financials
Market Cap
$85.96M
Trailing P/E
--
Forward P/E
-1.14
Beta (5Y)
--
52W High
$17.94
52W Low
$3.35
Avg Volume
291K
Day High
Day Low